Biologics Outsourcing Market Set for Strong Growth to US$ 64.57 Billion by 2033, Led by North America's 34.7% Market Share | Key Players - AbbVie Inc., WuXi Biologics, Charles River Laboratories

The Global Biologics Outsourcing Market size was at US$ 22.92 billion in 2024 and is expected to reach US$ 64.57 billion by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.

The market is experiencing significant growth as biopharmaceutical companies increasingly outsource development and manufacturing activities to improve operational efficiency, reduce production costs, and accelerate the commercialization of biologics. Rising demand for monoclonal antibodies, cell and gene therapies, biosimilars, and recombinant proteins, coupled with expanding biologics pipelines, is driving greater reliance on specialized contract development and manufacturing organizations (CDMOs).

Industry participants are increasingly investing in advanced bioprocessing technologies, flexible manufacturing facilities, and end-to-end outsourcing capabilities to meet evolving regulatory standards and growing global demand. Companies that strengthen expertise in high-value biologics production, process optimization, and next-generation therapeutic manufacturing are expected to secure long-term competitive advantages through strategic partnerships, enhanced scalability, and faster time-to-market.

Get a Free Sample PDF of this Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/biologics-outsourcing-market?ram

Key Industry Developments

United States:
✅ June 2026: AGC Biologics entered a strategic partnership with Pyramid Pharma Services to provide integrated U.S.-based biologics outsourcing from drug substance manufacturing through sterile fill-finish and device assembly. The collaboration expands end-to-end CDMO capabilities for clinical biologics, reducing development timelines and strengthening domestic manufacturing capacity through advanced fill-finish technologies.

✅ June 2026: Lonza enhanced its biologics development platform with an integrated DNA-to-IND offering featuring the new GS Ori-GoTM vector technology. The innovation improves cell-line productivity, accelerates preclinical development, and helps outsourced biologics programs reach IND readiness faster while reducing development risk.

✅ March 2026: FUJIFILM Biotechnologies launched ShunzymeXTM, a proprietary precision purification technology for complex biologics manufacturing. Developed with the University of Edinburgh, the platform simplifies downstream processing, improves purification efficiency, and accelerates GMP readiness for outsourced biologics production.

Japan:
✅ October 2025: Rentschler Biopharma expanded its biologics outsourcing activities in Japan by introducing its Rentschler Expression Platform and advanced development services at BioProcess International Asia in Kyoto. The initiative strengthens regional CDMO support with accelerated cell-line development and optimized biologics manufacturing solutions tailored for Japanese biopharma companies.

✅ December 2025: Samsung Biologics announced the acquisition of a U.S. biologics manufacturing facility from GSK while continuing expansion to support Japanese pharmaceutical customers. The investment enhances global biologics outsourcing capacity, strengthens advanced manufacturing capabilities, and supports multinational clients, including Japanese innovators.

✅ October 2025: Samsung Biologics reported that it had secured contracts with nearly half of Japan's top 10 pharmaceutical companies, supported by its Tokyo commercial expansion. The company continued strengthening biologics outsourcing services for Japanese drug developers through closer regional engagement and expanding CDMO capabilities.

Strategic Acquisitions & Partnerships
✅ Lonza - Strategic Partnership Expansion
(July, 2026)
Lonza expanded its long-term strategic collaboration with a leading U.S.-based biopharmaceutical company by adding two commercial biologics programs, with options for two additional programs. The agreement strengthens Lonza's biologics CDMO pipeline and reflects sustained demand for outsourced biologics development and manufacturing services.

✅ Samsung Biologics - Acquisition
(March, 2026)
Samsung Biologics completed its acquisition of GSK's biologics manufacturing facility in Rockville, Maryland, establishing its first U.S. manufacturing base. The acquisition added approximately 60,000 liters of biologics manufacturing capacity and expanded Samsung Biologics' global CDMO footprint for clinical and commercial biologics production.

Key Players:
AbbVie Inc. | Boehringer Ingelheim International GmbH | Catalent, Inc. (Novo Holdings) | Charles River Laboratories | WuXi Biologics | CordenPharma | Rentschler Biopharma SE | Syngene International Limited

Key Highlights: Top 5 Key Players in Biologics Outsourcing Market 2026
-WuXi Biologics: Expanded its integrated CRDMO platform with advanced end-to-end biologics development and manufacturing services, while strengthening continuous bioprocessing, high-concentration formulation, and commercial-scale manufacturing capabilities for monoclonal antibodies, bispecific antibodies, and other next-generation biologics.

-Boehringer Ingelheim International GmbH: Enhanced its BioXcellence contract manufacturing platform by expanding microbial and mammalian biopharmaceutical production capabilities, alongside introducing advanced cell line development and scalable manufacturing solutions to accelerate biologics from clinical development to commercial supply.

-Catalent (Novo Holdings): Advanced its biologics CDMO capabilities through expanded biologics drug substance and sterile fill-finish services, while strengthening support for antibody-based therapeutics, gene therapies, and integrated clinical-to-commercial manufacturing solutions.

-Charles River Laboratories: Strengthened its biologics outsourcing portfolio by expanding integrated discovery, preclinical development, analytical testing, and biologics manufacturing support, while enhancing cell therapy quality control and biologics testing services to streamline development timelines.

-Syngene International Limited: Expanded its biologics research and manufacturing capabilities with larger-scale microbial and mammalian manufacturing infrastructure, while enhancing integrated discovery, process development, analytical characterization, and GMP manufacturing services for monoclonal antibodies and recombinant biologics.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biologics-outsourcing-market?ram

Main Drivers and Trends Shaping the Future of the Biologics Outsourcing Market
-Growing Biologics Pipeline: Rising development of monoclonal antibodies, cell and gene therapies, biosimilars, and recombinant proteins is driving pharmaceutical and biotechnology companies to outsource manufacturing, analytical testing, and fill-finish operations to specialized CDMOs with advanced capabilities.

-Capacity Expansion & Advanced Manufacturing: Increasing investments in single-use bioprocessing systems, continuous manufacturing, high-throughput process development, and digitalized production facilities are improving scalability, reducing costs, and accelerating commercial biologics production.

-Regulatory & Quality Focus: Stricter global GMP requirements and the need for robust quality assurance encourage companies to partner with experienced outsourcing providers offering regulatory expertise, validated manufacturing processes, and comprehensive compliance support across global markets.

-Market Challenges: High capital requirements for biologics manufacturing, complex technology transfer, skilled workforce shortages, supply chain risks, and evolving regulatory expectations continue to limit rapid expansion despite strong demand for outsourced biologics development and manufacturing services.

Regional Insights:
-North America: 34.7% (Largest share, driven by the presence of leading biopharmaceutical companies, advanced biologics manufacturing infrastructure, strong CDMO/CDMO outsourcing adoption, and significant R&D investments in the U.S. and Canada.)

-Asia Pacific: 30.2% (Fastest-growing region, fueled by expanding biologics manufacturing capacity in China, India, South Korea, and Japan, lower production costs, increasing regulatory compliance, and rising outsourcing from global pharmaceutical companies.)

-Europe: 24.1% (Supported by a mature pharmaceutical ecosystem, strong GMP standards, established biologics CDMOs, and sustained investments in advanced biologics and biosimilar manufacturing across Germany, Switzerland, the U.K., and France.)

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biologics-outsourcing-market?ram

Market Segmentation Analysis:
-By Service Type: Process Development Leads Due to Complex Biologics Manufacturing
Process development remains the leading service segment, as biologics require extensive optimization of upstream and downstream manufacturing processes to ensure quality, scalability, and regulatory compliance. Cell development is another key segment, supporting the creation of stable, high-yield cell lines for therapeutic production. Analytical services play a critical role in characterization, stability testing, and quality assurance throughout development, while other services, including fill-finish operations and regulatory support, strengthen end-to-end outsourcing capabilities.

-By Product: Monoclonal Antibodies Dominate the Outsourcing Landscape
Monoclonal antibodies represent the largest product segment due to their widespread use in oncology, autoimmune, and rare disease treatments. Vaccines remain a significant category supported by expanding immunization programs and infectious disease preparedness. Cell and gene therapies are witnessing rapid outsourcing demand because of complex manufacturing requirements, while recombinant proteins continue to support therapeutic and diagnostic applications. Other biologics, including biosimilars and plasma-derived products, further expand outsourcing opportunities.

-By Process Stage: Commercial Manufacturing Holds the Largest Position
Commercial-stage outsourcing dominates as biopharmaceutical companies increasingly rely on external partners for large-scale production, regulatory compliance, and global supply chain support. Clinical-stage services are essential for manufacturing investigational biologics used in clinical trials, while research-stage outsourcing enables early discovery, process optimization, and preclinical development before candidates advance to clinical evaluation.

-By Source: Mammalian Expression Systems Lead Production
Mammalian cell systems dominate biologics manufacturing because they enable complex protein expression with human-like post-translational modifications, making them ideal for monoclonal antibodies and advanced biologics. Microorganism-based systems, including bacterial and yeast platforms, remain widely used for recombinant proteins and cost-efficient, high-volume production where simpler protein structures are sufficient.

-By Outsourcing Model: CDMOs Lead Through Integrated Services
Contract Development and Manufacturing Organizations (CDMOs) represent the leading outsourcing model by providing integrated development, scale-up, manufacturing, and commercialization services under one platform. Contract Manufacturing Organizations (CMOs) primarily focus on large-scale production, whereas Contract Research Organizations (CROs) specialize in research, preclinical studies, and clinical trial support, enabling faster product development.

-By End User: Biopharmaceutical Companies Drive Outsourcing Demand
Biotechnology companies are the primary end users due to their dependence on specialized external expertise and manufacturing infrastructure. Pharmaceutical companies increasingly outsource biologics production to improve flexibility and reduce capital investment. Research organizations support innovation through discovery and early-stage development, while other end users, including academic institutions and healthcare organizations, contribute to specialized biologics research and production.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.